Health care leaders in southern Illinois are urging families to schedule back-to-school physicals and vaccinations well before the new academic year begins. By acting now, parents can manage requirements, avoid a late-season rush, and keep their children’s health on track.

A newly approved weight-loss drug, Foundayo (orforglipron), has arrived months ahead of schedule after gaining FDA clearance in just 50 days. The swift approval signals a growing momentum in the development of anti-obesity treatments.

Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, bringing the FDA-approved Enbumyst nasal spray into its cardiovascular portfolio. This first-in-class nasal spray loop diuretic helps manage fluid retention for congestive heart failure, marking a new step in Esperion’s plan to address the growing global burden of cardiometabolic disease. Executives anticipate that Enbumyst will bolster the company’s commercial capabilities and revenue growth.

Neutrolis, Inc. has released positive results from the Phase 1a portion of its LIBERATE-I trial, spotlighting NTR-1011’s potential in dismantling harmful Neutrophil Extracellular Traps (NETs). This first-in-class DNASE1L3 fusion protein aims to address chronic inflammatory pathways without compromising the immune system.

Heart health doesn’t exist in isolation. According to available information, medical experts stress that closely monitoring blood sugar and kidney function can play a critical role in comprehensive cardiovascular care.

Chronic Fatigue Syndrome (CFS) continues to confound medical experts and patients alike, affecting millions of Americans. New evidence suggests that nearly half of CFS cases may be tied to tick-borne infections, sparking urgent questions about diagnosis and accurate case counts.

Brii Biosciences announced full-year 2025 results, emphasizing progress in its hepatitis B treatments and a robust cash position of US$276.1 million. The Company’s Phase 2b HBV trials, ENRICH and ENHANCE, have fully enrolled and are poised for key data readouts in the second half of 2026.

University of Mississippi students have a unique chance to help save an 11-year-old Mississippi girl’s life this week. By joining the national bone marrow donor registry, they could offer hope and potentially provide a life-saving match.

Research suggests that the time of day when certain treatments—such as cancer therapies or vaccines—are given can influence their effectiveness. Scientists are examining how the body’s internal clock, or circadian rhythm, might be the key to unlocking better patient outcomes.

IgA nephropathy is a silent attack on the kidneys that often goes unnoticed. With new treatments on the horizon, early diagnosis could save countless lives by preventing further damage and prolonging kidney function.

A new generation of medications first developed for diabetes is now offering hope for chronic kidney disease patients. Three types of these drugs, including one famously known as Ozempic, are transforming the outlook for individuals who have long waited for more effective treatment options.

Cholesterol is recognized as a crucial factor for heart wellness. Although the full story remains behind a paywall, the overarching message points toward the importance of staying informed about this vital element of cardiovascular health.

Mdxhealth has unveiled new findings from Oxford’s ProMPT Study, which show that the Genomic Prostate Score (GPS) test can predict adverse outcomes for prostate cancer patients. Presented at EAU 2026, this research highlights the test’s broad relevance across multiple treatment approaches.

A stray cat bit a Lawton resident and was later confirmed to have rabies, according to the Oklahoma State Department of Health. The incident highlights the ongoing need for vigilance regarding the virus.

A far-reaching survey from the Bladder Cancer Advocacy Network (BCAN) reveals that countless patients still face late diagnoses and limited support despite medical advancements. More than 1,100 respondents from nearly every state report gaps not only in financial protection but also in mental health services.

At 35, runner Erica Blackburn discovered that her longtime passion was jeopardized by varicose veins. This article explores how she found relief through a targeted treatment, enabling her to return to the active life she loves.

CervoMed plans to present vital data at the upcoming AD/PD™ 2026 Scientific Conference, reinforcing the rationale for its Phase 3 dementia trial. The findings aim to shed new light on patient population and dosing regimen decisions.

Xenon Pharmaceuticals Inc. has announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner, a novel KV7 potassium channel opener, in treating focal onset seizures. This milestone underscores the company’s commitment to advancing life-changing therapeutics for patients with epilepsy and depression.

A spring workshop series titled “Healthy Living with Diabetes” is open for registration until April 9. Organized by the Aging and Disability Resource Center of Barron and Rusk counties, this program promises to guide participants in more effectively managing diabetes.

One reader’s fears about thyroid cancer and a family history prompt questions about Hashimoto’s disease. A social media site recommends eliminating gluten, dairy, tofu, and tomatoes—raising deeper inquiries about effective dietary changes and the realities of risk.

Diabetes affects millions worldwide, and new efforts highlight how cultural traditions might hold the key to better nutrition. By honoring time-tested recipes, family values, and community support, advocates hope to encourage healthier choices and more sustainable habits.